Less frequent HPV tests detect precancerous lesions of the cervix just as well as more frequent Pap smears, which could help achieve The goal of eliminating the cancer. When it comes to detecting precancerous...
Researchers at the AACR Annual Meeting 2024 examined new treatment options for brain tumors.
Disparities in cancer outcomes shrink but persist, and FDA approval increases access to HPV screening.
Tarlatamab-dlle is the first t-cell engager that uses the bispecific antibody design for a solid tumor. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tarlatamab-dlle (Imdelltra) to treat patients with...
Insights from the AACR Cancer Disparities Progress Report 2024.
The CAR T-cell therapy received accelerated approval to treat advanced cases of pretreated follicular lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lisocabtagene maraleucel (Breyanzi) for the treatment of...
New research fuels progress in cancer survival, prevention and side effect management.
People may be able to wait longer between colonoscopies, and a trial evaluates a less invasive option for treating prostate cancer.
Updated recommendation lowers age for breast cancer screening, and laboratory tests will undergo greater FDA oversight.
Tisotumab vedotin-tftv is approved to treat certain recurrent or metastatic cervical cancers. The U.S. Food and Drug Administration (FDA) has approved tisotumab vedotin-tftv (Tivdak) for patients with recurrent or metastatic cervical cancer whose disease...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More